| XOMA ROYALTY |
| USA |
| Gesundheit |
| US98419J2069 / A2ATUH |
| X0M1 (Frankfurt) / XOMA (NASDAQ) |
| FRA:X0M1, ETR:X0M1, X0M1:GR, NASDAQ:XOMA |
| - |
| https://www.xoma.com/ |
|
XOMA Corporation is an innovative biotechnology company that specializes in the discovery, development, and licensing of antibody therapeutics. The primary aim of the company is to license its drug candidates and proprietary platform to other pharmac..
>Volltext.. |
| 341.19 Mio. EUR |
| 394.71 Mio. EUR |
| 45.18 Mio. EUR |
| 12.44 Mio. EUR |
| 21.1 Mio. EUR |
| 1.33 EUR |
| 113.97 Mio. EUR |
| 76.54 Mio. EUR |
| 2.42 Mio. EUR |
| 2.55 |
| 61.35% |
| - |
| - |
| - |
| - |
| 03.01.25 - 0.46251348€ 02.04.24 - 0.49647427€ |
| - |
| XOMA ROYALTY |
| 05.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|